Heron Therapeutics Reports Robust Q2 2025 Performance and Strategic Initiatives Heron Therapeutics announces a strong financial performance in Q2 2025, highlighting key commercial growth and strategic developments for their acute care and oncology products.

Heron Therapeutics Reports Robust Q2 2025 Performance and Strategic Initiatives #USA #CARY #Heron_Therapeutics #ZYNRELEF #APONVIE

Heron Therapeutics Reports Strong Q1 2025 Financial Results and Corporate Updates Heron Therapeutics has shared impressive financial results for Q1 2025, showcasing significant growth and key updates on their products and corporate strategies.

Heron Therapeutics Reports Strong Q1 2025 Financial Results and Corporate Updates #United_States #CARY #Heron_Therapeutics #ZYNRELEF #APONVIE

Heron Therapeutics Reports Financial Achievements and Strategic Developments for 2024 Heron Therapeutics has released its financial report for Q4 and the full year 2024, showcasing key developments and growth strategies for future success.

Heron Therapeutics Reports Financial Achievements and Strategic Developments for 2024 #USA #CINVANTI #Heron_Therapeutics #Cary,_North_Carolina #ZYNRELEF